REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Bradykinin Receptor 2 Antibodies

Close filters
No results were found for the filter!
NEW
Agonist-induced Threonine372/Serine373 phosphorylation of the Bradykinin Receptor 2
pT372/pS373-B2 (phospho-Bradykinin Receptor 2...
Threonine372/Serine373 (T372/S373) is major phosphorylation site of the Bradykinin Receptor 2 (B2). The pT372/pS373-B2 antibody detects phosphorylation in response to agonists. T372/S373 phosphorylation is likely to be involved in...
$ 350.00
Details
NEW
Agonist-induced Serine366/Threonine369 phosphorylation of the Bradykinin Receptor 2
pS366/pT369-B2 (phospho-Bradykinin Receptor 2...
Serine366/Threonine369 (S366/T369) is major phosphorylation site of the Bradykinin Receptor 2 (B2). The pS366/pT369-B2 antibody detects phosphorylation in response to agonists. S366/T369 phosphorylation is likely to be involved in...
$ 350.00
Details
NEW
Validation of the Bradykinin Receptor 2 in transfected HEK293 cells
B2 (non-phospho-Bradykinin Receptor 2 Antibody)
The non-phospho-B2 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human B2. It can be used to detect total B2 receptors in Western blots independent of phosphorylation. The non-phospho-B2 antibody...
$ 350.00
Details

B2

Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during acute inflammation, and its receptors, B1 and B2, are expressed on eosinophils, and neutrophils.The B2 antagonist Icatibant (Firazyr) is approved in the US and EU for the treatment of acute attacks of hereditary angioedema. B2 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine366/threonine369 (pS366/pT369-B2) and threonine372/serine373 (pT372/pS373-B2). This nomenclature refers to the human B2 receptor. This phosphorylation motif is highly conserved across species but corresponds to pS367/pT370-B2 and pT373/pS374-B2 in mice and pS371/pT374-B2 and pT377/pS378-B2 in rats. For more information on B2 pharmacology please refer to the IUPHAR database. For further reading refer to:

Coulson J, Couture R, Faussner A, Gobeil Jr F, Leeb-Lundberg F, Marceau F, Muller-Esterl W, Pettibone D, Zuraw B. Bradykinin receptors in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4). Available from: https://doi.org/10.2218/gtopdb/F10/2019.4.

Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during... read more »
Close window
Bradykinin Receptor 2 Antibodies

B2

Bradykinin receptor 2 (B2) are activated by the endogenous peptides bradykinin (BK) and Lys-BK (kallidin). Bradykinin is a vasoactive, pain inducing and pro-inflammatory kinin released during acute inflammation, and its receptors, B1 and B2, are expressed on eosinophils, and neutrophils.The B2 antagonist Icatibant (Firazyr) is approved in the US and EU for the treatment of acute attacks of hereditary angioedema. B2 receptor desensitization, β-arrestin recruitment and internalization are regulated by phosphorylation of carboxyl-terminal serine366/threonine369 (pS366/pT369-B2) and threonine372/serine373 (pT372/pS373-B2). This nomenclature refers to the human B2 receptor. This phosphorylation motif is highly conserved across species but corresponds to pS367/pT370-B2 and pT373/pS374-B2 in mice and pS371/pT374-B2 and pT377/pS378-B2 in rats. For more information on B2 pharmacology please refer to the IUPHAR database. For further reading refer to:

Coulson J, Couture R, Faussner A, Gobeil Jr F, Leeb-Lundberg F, Marceau F, Muller-Esterl W, Pettibone D, Zuraw B. Bradykinin receptors in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4). Available from: https://doi.org/10.2218/gtopdb/F10/2019.4.

Recently viewed